The expanding role for small molecules in immuno-oncology

Area of Science:

• Oncology
• Immunology
• Pharmacology

Background:

• Immune checkpoint inhibition (ICI) using PD1/PDL1 antibodies has revolutionized cancer treatment.
• There is a growing interest in small-molecule immuno-oncology drugs targeting intracellular pathways.
• Small molecules targeting pro-tumorigenic pathways show immunostimulatory effects that synergize with ICI.

Purpose of the Study:

• To review recent advancements in small-molecule immuno-oncology drug development.
• To discuss challenges and future directions for combining small molecules with ICI.
• To highlight the synergistic potential of small molecules in enhancing cancer immunotherapy.

Main Methods:

• Review of current literature on small-molecule immuno-oncology drugs.
• Analysis of clinical trial data for combination therapies.
• Discussion of drug development milestones and hurdles.

Main Results:

• Several small-molecule immuno-oncology drugs targeting intracellular pathways are in clinical trials.
• Combinations of small molecules with ICI antibodies are demonstrating synergistic effects.
• Approved combination regimens involving small molecules and ICI are increasing.

Conclusions:

• Small molecules represent a promising complementary strategy to enhance ICI therapy.
• Targeting cancer metabolism, cytokine/chemokine, innate immunity, and T cell checkpoints with small molecules are key areas of investigation.
• Further research and clinical development are crucial for optimizing small-molecule and ICI combinations for improved cancer patient outcomes.